Radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Abstract

Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.

• Authors: Grzegorz S Nowakowski, Thomas E Witzig
• Journal: Clinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 4 Issue 3 Pg. 225-31 (Mar 2006) ISSN: 1543-0790 [Print] United States
• PMID: 16728934 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antigens, CD20

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antigens, CD20 (immunology)
• Humans
• Lymphoma, B-Cell (drug therapy, radiotherapy)
• Radioimmunotherapy (methods)
• Treatment Outcome